Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 22nd January, 2019 as per the details mentioned in the attached file. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of Notice of Board Meeting published in English and vernacular language (Gujarati) newspaper on 9th January, 2019 in Economic Times English and Gujarati Edition. Alembic Pharmaceuticals Ltd - 533573 - Shareholding for the Period Ended December 31, 2018
Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click here Alembic Pharmaceuticals Ltd - 533573 - Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer Alembic Pharmaceuticals Ltd - 533573 - Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter And Nine Months Period Ended 31St December, 2018.
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/01/2019 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the quarter and nine months period ended 31st December, 2018. The trading window shall remain closed from 19th January, 2019 to 24th January, 2019 for the above referred purpose. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) in English language newspaper - Business Standard on 4th January, 2019. Alembic Pharmaceuticals Ltd - 533573 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Alembic Pharmaceuticals Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate. Alembic Pharma gets USFDA nod for Parkinson's treatment drug
The company, now, has 84 ANDA approvals from USFDA Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval Pramipexole Dihydrochloride Extended-Release Tablets, 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, and 4.5 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisements related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 26th December, 2018.